Use and discontinued use of menopausal hormone therapy by healthy women in Norway: The Hordaland women's cohort study

Menopause

Volumn 21, Issue 5, 2014, Pages 459-468

  Espen Gjelsvik, Bjørn ^a   Straand, Jørund ^a   Hunskaar, Steinar ^b   Dalen, Ingvild ^a   Rosvold, Elin O ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cohort study; Hormone treatment; Norway; Predictors; Treatment cessation

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; CLIMACTERIUM; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIVORCED PERSON; DRUG UTILIZATION; DRUG WITHDRAWAL; FEAR; FEMALE; FOLLOW UP; HEALTH SURVEY; HORMONAL THERAPY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MARRIED PERSON; MENOPAUSE; NIGHT SWEAT; NORWAY; ONSET AGE; POSTMENOPAUSE; RURAL AREA; SIDE EFFECT; SMOKING; VAGINAL DRYNESS; ESTROGEN THERAPY; PHYSIOLOGY; STATISTICAL MODEL; UTILIZATION; WOMEN'S HEALTH;

ADULT; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; MENOPAUSE; NORWAY; WOMEN'S HEALTH;

EID: 84899988341     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0b013e3182a11f2d     Document Type: Article

References (47)

1. Hunskår S, Hannestad YS, Backe B, Matheson I. [Attitudes of Norwegiangeneral practitioners to prescription of estrogens 1990-92]. TidsskrNor Laegeforen 1994;114:2095-2098.
2. Topo P, Koster A, Holte A, et al. Trends in the use of climacteric andpostclimacteric hormones in Nordic countries. Maturitas 1995;22:89-95.
3. Malterud K. Illness or Character A Critical Book About Women andHealth Sykdom eller s&rpreg En kritisk bok om kvinner og helse. Oslo,Norway: Pax Forlag, 1984.
4. Bakken K, Eggen AE, Lund E. Hormone replacement therapy in Norwegianwomen, 1996-1997. Maturitas 2001;40:131-141.
5. Backe B, Hunskaar S. Increased acceptance of HRT and improved levelof information: a change in Norwegian women's opinion from 1990 to1997. Acta Obstet Gynecol Scand 2001;80:623-627.
6. Treatment With Oestrogen. Report No. 131. Stockholm, Sweden:SBUVSwedish Council on Health Technology Assessment, 1996.
7. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapyand incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002;288:2123-2129.
8. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent diseaseand prolong life in postmenopausal women. Ann Intern Med1992;117:1016- 1037.
9. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogentherapy and cardiovascular disease. Ten-year follow-up from the Nurses'Health Study. N Engl J Med 1991;325:756-762.
10. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronaryheart disease: a quantitative assessment of the epidemiologic evidence.Prev Med 1991;20:47-63.
11. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, StampferMJ. A prospective, observational study of postmenopausal hormonetherapy and primary prevention of cardiovascular disease. Ann InternMed 2000;133:933-941.
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogenplus progestin in healthy postmenopausal women: principal resultsfrom the Women's Health Initiative randomized controlled trial. JAMA2002;288:321-333.
13. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomesduring 6.8 years of hormone therapy: Heart and Estrogen/progestin ReplacementStudy follow-up (HERS II). JAMA 2002;288:49-57.
14. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plusprogestin for secondary prevention of coronary heart disease in postmenopausalwomen. Heart and Estrogen/progestin Replacement Study(HERS) Research Group. JAMA 1998;280:605-613.
15. Beral V; Million Women Study Collaborators. Breast cancer and hormonereplacementtherapy in the Million Women Study. Lancet 2003;362:419-427.
16. Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement therapyand incidence of hormone-dependent cancers in the Norwegian Womenand Cancer study. Int J Cancer 2004;112:130-134.
17. Waaseth M, Bakken K, Lund E. Patterns of hormone therapy use in theNorwegian Women and Cancer study (NOWAC) 1996-2005. Maturitas2009;63:220-226.
18. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausalhormone therapy: annual trends and response to recent evidence. JAMA2004;291:47-53.
19. Hoffmann M, Hammar M, Kjellgren KI, Lindh-Astrand L, Brynhildsen J.Changes in women's attitudes towards and use of hormone therapy afterHERS and WHI. Maturitas 2005;52:11-17.
20. Ekstrom H. Trends in middle-aged women's reports of symptoms, use ofhormone therapy and attitudes towards it. Maturitas 2005;52:154-164.
21. Norwegian Medicines Agency. [Hormone therapy for women withmenopausal symptoms; no 2]. Nytt Legemid [serial online] 2003:3-4.22.
22. Gjelsvik B, Swensen E, Hjortdahl P. [The general practitioner's view onhormone replacement therapy during and after menopause]. Tidsskr NorLaegeforen 2007;127:1500-1503.
23. Hallquist AC, Moen MH, Andrew M, Aursnes I. [Attitudes to estrogenreplacement therapy among Norwegian women]. Tidsskr Nor Laegeforen2006;126:1195-1197.
24. The Hordaland Health Study (HUSK). Available at: http://husk.b.uib.no/ [serial online]. Accessed November 22, 2012.
25. Jahanlu D, Qureshi SA, Hunskaar S. The Hordaland Women's Cohort: aprospective cohort study of incontinence, other urinary tract symptomsand related health issues in middle-aged women. BMC Public Health2008;8:296.
26. Gjelsvik B, Rosvold EO, Straand J, Dalen I, Hunskaar S. Symptomprevalence during menopause and factors associated with symptoms andmenopausal age. Results from the Norwegian Hordaland Women's Cohortstudy. Maturitas 2011;70:383-390.
27. Jahanlu D, Hunskaar S. The Hordaland Women's Cohort: prevalence, incidence, and remission of urinary incontinence in middle-aged women.Int Urogynecol J Pelvic Floor Dysfunct 2010;21:1223-1229.
28. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages ofReproductive Aging Workshop (STRAW). Fertil Steril 2001;76:874-878.
29. Levesque R, Painter J. Propensity scoreVSPSS syntax. Availableat: http://www.unc.edu/~painter/SPSSsyntax/propen.txt [serial online].Accessed June 1, 2012.
30. Rosenbaum PR, Rubin DB. The central role of the propensity score inobservational studies for causal effects. Biometrika 1983;70:41-55.
31. Fournier A, Weiderpass E. Characteristics and recent evolution of menopausalhormone therapy use in a cohort of Swedish women. Climacteric2009;12: 410-418.
32. Lindh-Astrand L, Brynhildsen J, Hoffman M, Hammar M. Vasomotorsymptoms usually reappear after cessation of postmenopausal hormonetherapy: a Swedish populationYbased study. Menopause 2009;16:1213-1217.
33. Williams RE, Kalilani L, DiBenedetti DB, Zhou X, Fehnel SE, Clark RV.Healthcare seeking and treatment for menopausal symptoms in theUnited States. Maturitas 2007;58:348-358.
34. Backe B, Hunskaar S, Skolbekken JA. General practitioners' attitudes tooestrogen prescription in the menopause: a national survey in Norway.Scand J Prim Health Care 1992;10:179-184.
35. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormonetherapy and risk of cardiovascular disease by age and years since menopause.JAMA 2007;297:1465-1477.
36. Gjelsvik B. [General practitioners' advice on hormone replacementtherapy in menopause]. Tidsskr Nor Laegeforen 2008;128:1660-1663.
37. Ness J, Aronow WS, Beck G. Menopausal symptoms after cessation ofhormone replacement therapy. Maturitas 2006;53:356-361.
38. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotorsymptoms of menopause: a meta-analysis. J Gen Intern Med 2008;23:1507-1513.
39. Haimov-Kochman R, Barak-Glantz E, Arbel R, et al. Gradual discontinuationof hormone therapy does not prevent the reappearance of climactericsymptoms: a randomized prospective study. Menopause 2006;13:370-376.
40. Haskell SG, Bean-Mayberry B, Gordon K. Discontinuing postmenopausalhormone therapy: an observational study of tapering versus quittingcold turkey: is there a difference in recurrence of menopausal symptoms? Menopause 2009;16:494-499.
41. Cuypers K, Krokstad S, Lingaas Holmen T, Skjei Knudtsen M, BygrenLO, Holmen J. Patterns of receptive and creative cultural activities andtheir association with perceived health, anxiety, depression and satisfactionwith life among adults: the HUNT study, Norway. J EpidemiolCommunity Health 2012;66:698-703.
42. Schou MB, Krokstad S, Westin S. [How is self-rated health associatedwith mortality?]. Tidsskr Nor Laegeforen 2006;126:2644-2647.
43. Young H, Grundy E, O'Reilly D, Boyle P. Self-rated health and mortalityin the UK: results from the first comparative analysis of the England andWales, Scotland, and Northern Ireland Longitudinal Studies. PopulTrends 2010;139:11-36.
44. Singh-Manoux A, Gueguen A, Martikainen P, Ferrie J, Marmot M,Shipley M. Self-rated health and mortality: short-and long-term associationsin the Whitehall II Study. Psychosom Med 2007;69:138-143.
45. Avis NE, Assmann SF, Kravitz HM, Ganz PA, Ory M. Quality of life indiverse groups of midlife women: assessing the influence of menopause,health status and psychosocial and demographic factors. Qual Life Res2004;13:933-946.
46. Greenblum CA, Rowe MA, Neff DF, Greenblum JS. Midlife women:symptoms associated with menopausal transition and early postmenopauseand quality of life. Menopause 2013;20:22-27.
47. Avis NE, Ory M, Matthews KA, Schocken M, Bromberger J, Colvin A.Health-related quality of life in a multiethnic sample of middle-agedwomen: Study of Women's Health Across the Nation (SWAN). MedCare 2003;41:1262-1276.